Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） is a phase 2, interventional study registered as NCT06647680 by The Affiliated Hospital of Qingdao University, with a registry enrolment figure of 35 participants, started 2025-06-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles. Conditions listed: Rectal Cancer Patients. Primary outcome: Clinical complete response and pathological complete response. Colorectal eligibility wording from the registry: "* Pathologically proven diagnosis of adenocarcinoma of the rectum". Sites: China. No results are recorded here; the registry entry is the source.